713 related articles for article (PubMed ID: 27434660)
21. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome.
Jindra P; Raida L; Karas M; Szotkowski T; Lysák D; Hrabětová M; Jungová A; Steinerová K; Faber E; Papajík T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):462-469. PubMed ID: 31109905
[TBL] [Abstract][Full Text] [Related]
22. [The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Zu YL; Zhang YL; Zhou J; Han LJ; Zhao HF; Gui RR; Hou YJ; Song YP
Zhonghua Nei Ke Za Zhi; 2016 Aug; 55(8):634-6. PubMed ID: 27480560
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.
Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617
[TBL] [Abstract][Full Text] [Related]
25. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Badar T; Kantarjian HM; Nogueras-Gonzalez GM; Borthakur G; Garcia Manero G; Andreeff M; Konopleva M; Kadia TM; Daver N; Wierda WG; Luthra R; Patel K; Oran B; Champlin R; Ravandi F; Cortes JE
Am J Hematol; 2015 Nov; 90(11):1065-70. PubMed ID: 26299958
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Hu B; Vikas P; Mohty M; Savani BN
Expert Rev Hematol; 2014 Apr; 7(2):301-15. PubMed ID: 24308526
[TBL] [Abstract][Full Text] [Related]
27. [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan ZP; Zhang Y; Xu N; Ye JY; Zhou X; Wang ZX; Sun J; Liu QF; Huang F
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):351-354. PubMed ID: 29747291
[TBL] [Abstract][Full Text] [Related]
28. [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Zhang Y; Xuan L; Fan Z; Huang F; Jiang Q; Xu N; Gao Y; Sun J; Liu Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):292-6. PubMed ID: 27093991
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
Sammons SL; Pratz KW; Smith BD; Karp JE; Emadi A
Am J Hematol; 2014 Sep; 89(9):936-8. PubMed ID: 24898801
[No Abstract] [Full Text] [Related]
30. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
31. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia.
Schechter T; Gassas A; Chen H; Pollard J; Meshinchi S; Zaidman I; Hitzler J; Abdelhaleem M; Ho R; Domm J; Woolfrey A; Frangoul H
Biol Blood Marrow Transplant; 2015 Jan; 21(1):172-5. PubMed ID: 25139215
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Rautenberg C; Nachtkamp K; Dienst A; Schmidt PV; Heyn C; Kondakci M; Germing U; Haas R; Kobbe G; Schroeder T
Eur J Haematol; 2017 Apr; 98(4):348-354. PubMed ID: 27893163
[TBL] [Abstract][Full Text] [Related]
33. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
34. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
[TBL] [Abstract][Full Text] [Related]
36. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
37. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
38. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
39. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158
[TBL] [Abstract][Full Text] [Related]
40. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]